comparemela.com

Latest Breaking News On - Oral paclitaxel plus encequidar - Page 2 : comparemela.com

ATNX SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc

Home / Top News / ATNX SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc. ATNX SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc. NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) from August 7, 2019 through February 26, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the Western District of New York alleges violations of the Securities Exchange Act of 1934.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc , of Class Action Lawsuit and Upcoming Deadline

Share this article Share this article NEW YORK, April 6, 2021 /PRNewswire/  Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. ( Athenex or the Company ) (NASDAQ: ATNX) and certain of its officers. The class action, filed in the United States District Court for the Western District of New York, and docketed under 21-cv-00413, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquire Athenex common stock between August 7, 2019 and February 26, 2021, inclusive (the Class Period ). This action is brought on behalf of the Class for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ), 15 U.S.C. §§ 78j(b) and 78t(a) and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission, 17 C.F.R. § 240.10b-5.

ATNX INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc

ATNX INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

ATNX INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc

Athenex Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Athenex, Inc

Athenex Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Athenex, Inc. Kaplan Fox & Kilsheimer LLP NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com) is investigating claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX). On March 1, 2021, Athenex issued a press release reporting its fourth quarter results and disclosing receipt of a complete response letter (“CRL”) from the FDA regarding its new drug application for Oral Paclitaxel Plus Encequidar for the treatment of metastatic breast cancer. In the CRL, the FDA expressed the following: Concerns about safety risks associated with increase in neutropenia-related sequelae;

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.